Latest 8-K filings

NeuroOne Medical Technologies Corporation announced a 16% year-over-year increase in product revenue to $2.0 million for its third fiscal quarter ended June 30, 2026, alongside a significant expansion in gross margins to 59.9%.

Candel Therapeutics announced Q2 2026 results, highlighting progress in its aglatimagene prostate cancer program with a planned BLA submission in Q4 2026 and positive Phase 3 data published in The Lancet Oncology.

Pulmatrix announces Q2 2026 results, highlighting progress on its merger with Eos Senolytix and efforts to out-license or monetize its clinical assets.

Solo Brands announced its fiscal 2026 second quarter results, highlighting improved profitability and significant debt reduction despite a dip in net sales.

MeiraGTx reports strong Q2 2026 results, highlighted by the acquisition of botaretigene sparoparvovec, a $400 million strategic investment, and positive clinical data for AAV2-hAQP1.

Duke Robotics Corp. announced its second quarter 2026 financial results, highlighting an expanded Israel Electric Corporation contract, a new defense order, and a successful $9.2 million public offering and Nasdaq uplisting.

Veea Inc. has entered into an At Market Issuance Sales Agreement with Roth Capital Partners, LLC, allowing for the sale of up to $4.35 million in common stock.

The Elmet Group Co. announced robust second quarter 2026 financial results, featuring a 35.2% increase in revenue to $66.4 million and a significant expansion in gross profit margin.

Monro, Inc. announced its annual meeting results, including the election of directors and the declaration of a quarterly cash dividend of $0.28 per share.

Grace Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $15.8 million and providing an update on the ongoing efforts to resubmit its New Drug Application for GTx-104.

Venu Holding Corporation announced its second-quarter 2026 financial results, showcasing a substantial increase in total assets and progress on venue development and financing strategies.

Healthy Choice Wellness Corp. announced a 15-year, $1.25 billion take-or-pay lease agreement for 43 MW of IT load capacity at its Oklahoma data center.

Artius II Acquisition Inc. announced its board has decided to liquidate and dissolve the company as it cannot complete its initial business combination within the required timeframe.

Rekor Systems announced Q2 2026 results, showcasing a 23% sequential revenue increase to $12.7 million, improved adjusted gross margin to 56%, and a 79% year-over-year reduction in adjusted EBITDA loss.

SCI Engineered Materials, Inc. has announced a management transition with the resignation of its Chief Financial Officer, Shelby Yohn, who will remain with the company in a new role.

Accelerant Holdings announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valued at over $4 billion, while also reporting strong Q2 2026 financial results.

Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II study enrollment and a strengthened balance sheet with approximately $9.6 million in cash, supporting advancement of its Symphony IL-6 test toward regulatory submission and commercialization.

IREN Limited announced the successful delivery and acceptance of its Horizon 1 AI Cloud deployment by Microsoft, alongside achieving NVIDIA Exemplar Cloud status.

Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.

MiNK Therapeutics announced second quarter 2026 financial results and provided positive initial observations from its Phase 2 trial of agenT-797 in acute lung injury, alongside establishing a paid international named-patient access program.

Creative Realities announced record second quarter revenue of $21.5 million and an improved outlook, driven by strong service revenue growth and new major client wins.

Madison Square Garden Sports Corp. announced robust fiscal 2026 fourth quarter and full-year financial results, highlighted by the New York Knicks' NBA Championship win and progress on the proposed spin-off of its New York Rangers business.

Sprinklr, Inc. announced the appointment of Jordi Ribas, Ph.D., a prominent AI and product leader from Microsoft, to its Board of Directors, effective August 17, 2026.

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Intuitive Machines announced record Q2 2026 revenue of $206 million, up over four times year-over-year, and a record backlog of $1.8 billion, driven by significant new contract awards across commercial, civil, and national security sectors.

Advanced Flower Capital Inc. announced its second quarter 2026 financial results, reporting a net investment income of $3.5 million and an increase in net asset value per share to $8.25.

Cabaletta Bio announced second quarter 2026 financial results, detailing progress in its rese-cel clinical development program for autoimmune diseases and providing updates on manufacturing partnerships.

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

Beacon Financial Corporation presented its Q2 2026 investor update, showcasing improved profitability metrics, strong capital positions, and a strategic focus on commercial lending, while also addressing specific asset quality concerns.

Yesway, Inc. announced strong second quarter 2026 financial results, highlighted by record store contribution, increased net income, and a raised full-year Adjusted EBITDA outlook.